Tranzyme Pharma

Dr. Garg has served as President and Chief Executive Officer since September 2000 and as one of Tranzyme's directors since October 2000. Prior to joining Tranzyme, he served as Chief Operating Officer of Apex Bioscience, Inc. (now Curacyte AG of Munich, Germany), where he was responsible for establishing a major strategic alliance with a Japanese pharmaceutical company and advancing the company's lead product into Phase 2 clinical development. Earlier he was Vice President of Product Development and Manufacturing at DNX, Inc. (NASDAQ: DNXX), and held management positions at Sunovion Pharmaceuticals, Inc. (formerly known as Sepracor Inc.) (acquired by Dainippon Sumitomo Pharma) and Bio-Response Inc. (acquired by Baxter International, Inc.).

Dr. Rousseau has held the role of Chief Medical Officer at Tranzyme since October 2011. He joined Tranzyme Pharma from Gilead Sciences where he had served as Therapeutic Area Head and Vice President Hepatic Diseases, and oversaw the clinical development for several drugs which ultimately received global marketing approval. From 2003 to 2007, he held the position of Vice President, Clinical Research. During his tenure at Gilead, Dr. Rousseau was also head of the company's Durham facility. From 1997 to 2002, Dr. Rousseau was Chief Medical Officer of Triangle Pharmaceuticals until its acquisition by Gilead in 2003. He began his pharmaceutical industry career in 1993 at Wellcome Lab in Paris, France, followed by 2 years with Glaxo Wellcome in Research Triangle Park, N.C. from 1995-1997. Dr. Rousseau holds a Doctorate of Medicine and a Degree of Epidemiology and Nosocomial Infections from the University of Paris 7, Paris, France. He also holds a Degree of Statistics from the University of Paris 6, Paris, France.

Dr. Thomas has served as Senior Vice President, Research and Preclinical Development since June 2006. Prior to joining Tranzyme, Dr. Thomas served as Vice President, Development, of LymphoSign Inc., beginning in 2004. Before LymphoSign, Dr. Thomas spent fourteen years with CIBA/Novartis Pharma, A.G., where he held several top-level management positions in Europe and the United States, culminating in his appointment as Executive Director, Global Project Manager and Leader of the PRIDE (Proof of Research In Development) Team Oncology. While at Novartis, he directed the preclinical development of more than 25 drug candidates. A highly accomplished biochemist and toxicologist with an extensive and productive career in drug discovery and development, Dr. Thomas is an author of over 140 scientific articles, book chapters and abstracts as well as a co-inventor on numerous patents. Dr. Thomas received his Ph.D. in biochemistry and organic chemistry from the University of Hannover, Germany.

Mr. Moore has served as Chief Business Officer since January 2013. He joined Tranzyme in 2011 as Vice President, Commercial Operations and his responsibilities were increased in January 2012 to include the oversight of Business Development. Before joining Tranzyme, Mr. Moore was employed by Ortho-McNeil Janssen, a Johnson & Johnson company where he served as Group Director responsible for the commercialization of new pain therapeutics. He has experience in New Business Development, Disease Management / Market Development Campaigns, Launch Readiness and unique experience in developing Hospital and Payer Value Platforms. In addition, Mr. Moore held numerous positions of increasing responsibility in sales, sales management, training, market research, managed care account management and payer marketing. Mr. Moore received his MBA in marketing from Lehigh University and a degree in Health Policy from Thomas Jefferson University.

Dr. Peterson joined Tranzyme in 1999 to lead the chemistry Research and Development efforts during the technology development stage of the Company and the start of its drug discovery programs. Dr. Peterson, a synthetic chemist by training, received his Ph.D. in Organic Chemistry from Washington State University (Professor D. Matteson, 1987) on the asymmetric synthesis of chiral natural products. He conducted post-doctoral research at the University of Minnesota in the Department of Medicinal Chemistry (Professor R. Vince) with a focus on the discovery of new antiviral and antitumor chemotherapeutic agents. In 1989, he received a National Service Award from the National Institute of Health (US). In 1990, he joined the Agricultural Division of Monsanto Co. where he was involved in a number of aspects of the R & D process, including constructing a novel class of inhibitors for EPSP synthase and directing regulatory studies to support the registration of a new herbicide product. In 1993, Dr. Peterson moved to Advanced ChemTech, where he served in areas of increasing responsibility, culminating as Corporate Vice-President of Technology Development. While with ACT, he initiated R & D efforts in automated combinatorial library synthesis and solid phase organic chemistry. He is author or co-author of over eighty publications, abstracted presentations and patents plus one book chapter.